Pedro Henrique Reis-Barbosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pedro Henrique Reis-Barbosa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Alberto Mandarim-De-Lacerda
Laboratory of Morphometry, Metabolism, and Cardiovascular disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
8 shared publications - Marcia Barbosa Aguila
Laboratory of Morphometry, Metabolism, and Cardiovascular disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
5 shared publications - Thatiany Souza Marinho
Laboratory of Morphometry, Metabolism, and Cardiovascular disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
4 shared publications - Ilitch Aquino Marcondes-De-Castro
Laboratory of Morphometry, Metabolism, and Cardiovascular disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
3 shared publications - Aline Penna-De-Carvalho
Universidade do Estado do Rio de Janeiro, Brazil
1 shared publication - Julia Ferreira Giannini1 shared publication
Latest Publications
- 1 January 2026
- Published by Academia Nacional de Medicina in Anais da Academia Nacional de Medicina
- Vol. 197 (1)
Neuroinflamação Como Eixo Central no Envelhecimento Cerebral e nas Doenças Neurodegenerativas: Mecanismos, Consequências Funcionais e Perspectivas Terapêuticas
A neuroinflamação tem sido reconhecida como um eixo central na fisiopatologia do envelhecimento cerebral e das doenças neurodegenerativas. O envelhecimento populacional, associado à elevada prevalência de doenças cardiometabólicas, tem contribuído para o aumento expressivo das demências, incluindo a doença de Alzheimer e a doença de Parkinson. Evidências experimentais e humanas demonstram que a neuroinflamação crônica de baixo grau, caracterizada pela ativação persistente da micróglia e pela reatividade dos astrócitos, desempenha papel determinante na disfunção sináptica, na perda de plasticidade neural, na reorganização patológica dos circuitos neuronais e no declínio cognitivo progressivo. Em nível molecular, a liberação sustentada de citocinas pró-inflamatórias, o estresse oxidativo, a disfunção mitocondrial e a ativação de vias inflamatórias intracelulares estabelecem um ciclo autoperpetuante de inflamação e vulnerabilidade neuronal. Do ponto de vista funcional, esses processos afetam preferencialmente regiões com alta demanda metabólica e plasticidade, como o hipocampo e o córtex pré-frontal, resultando em déficits de memória, atenção, funções executivas e cognição social. Apesar das diferenças clínicas e anatômicas entre as doenças neurodegenerativas, a neuroinflamação emerge como um mecanismo convergente em condições como a doença de Alzheimer, a doença de Parkinson, a esclerose lateral amiotrófica e a esclerose múltipla. Nesse contexto, estratégias terapêuticas voltadas à modulação da inflamação cerebral têm ganhado destaque. Agonistas do receptor do peptídeo semelhante ao glucagon tipo 1 e ácidos graxos ômega-3 (EPA e DHA) apresentam potencial neuroprotetor ao modularem a ativação glial, reduzirem citocinas pró-inflamatórias e estresse oxidativo, e preservarem a função mitocondrial e a plasticidade sináptica. Entretanto, limitações translacionais ainda impõem desafios à ampla aplicação clínica.
- 1 January 2026
- Published by Academia Nacional de Medicina in Anais da Academia Nacional de Medicina
- Vol. 197 (1)
Neuroinflamação Como Eixo Central no Envelhecimento Cerebral e nas Doenças Neurodegenerativas: Mecanismos, Consequências Funcionais e Perspectivas Terapêuticas
A neuroinflamação tem sido reconhecida como um eixo central na fisiopatologia do envelhecimento cerebral e das doenças neurodegenerativas. O envelhecimento populacional, associado à elevada prevalência de doenças cardiometabólicas, tem contribuído para o aumento expressivo das demências, incluindo a doença de Alzheimer e a doença de Parkinson. Evidências experimentais e humanas demonstram que a neuroinflamação crônica de baixo grau, caracterizada pela ativação persistente da micróglia e pela reatividade dos astrócitos, desempenha papel determinante na disfunção sináptica, na perda de plasticidade neural, na reorganização patológica dos circuitos neuronais e no declínio cognitivo progressivo. Em nível molecular, a liberação sustentada de citocinas pró-inflamatórias, o estresse oxidativo, a disfunção mitocondrial e a ativação de vias inflamatórias intracelulares estabelecem um ciclo autoperpetuante de inflamação e vulnerabilidade neuronal. Do ponto de vista funcional, esses processos afetam preferencialmente regiões com alta demanda metabólica e plasticidade, como o hipocampo e o córtex pré-frontal, resultando em déficits de memória, atenção, funções executivas e cognição social. Apesar das diferenças clínicas e anatômicas entre as doenças neurodegenerativas, a neuroinflamação emerge como um mecanismo convergente em condições como a doença de Alzheimer, a doença de Parkinson, a esclerose lateral amiotrófica e a esclerose múltipla. Nesse contexto, estratégias terapêuticas voltadas à modulação da inflamação cerebral têm ganhado destaque. Agonistas do receptor do peptídeo semelhante ao glucagon tipo 1 e ácidos graxos ômega-3 (EPA e DHA) apresentam potencial neuroprotetor ao modularem a ativação glial, reduzirem citocinas pró-inflamatórias e estresse oxidativo, e preservarem a função mitocondrial e a plasticidade sináptica. Entretanto, limitações translacionais ainda impõem desafios à ampla aplicação clínica.
- 7 August 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (10) , 4613-4621
The dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
Aim: Tirzepatide (Tzp), a novel dual agonist glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1, is approved for treating insulin resistance and obesity, and menopausal women consuming a high‐calorie diet are a target to study the Tzp effect. Therefore, we aimed to allometrically scale body weight (BW) in Tzp‐treated obese diabetic menopausal mice. Materials and Methods: Three‐month‐old C57BL/6 female mice had bilateral ovariectomy (Ovx) or a sham procedure and for 12 weeks were fed a control diet or a high‐fat and high sucrose diet ( n = 120/each group [control (C), obese diabetic (Od), Ovx (O), sham (S), Tzp (T)]). Tzp was subcutaneously administered (10 nmol/kg) or vehicle once a day for an additional 4 weeks. The analysis considered log‐transformed data and the allometric equation log y = log a + b log x . Results: Od and OdO showed more upward slopes than C and CO. In C, BW was non‐allometric by T administration. Od and OdO showed slightly positive slopes (more prominent in OdO than Od). OdT and OdOT showed negative slopes, significant intercepts, and more robust Pearson coefficients than untreated ones. A potent drug effect was seen with BW allometric decline. Interactions between diet versus Ovx and diet versus Tzp affected weight gain. Diet versus Ovx versus Tzp affected food intake. Conclusions: A model was developed to show three usual factors observed in mature women. Notably, Tzp improved the metabolism and weight loss of OdO mice. Tzp‐treated mice showed negative allometric BW across treatment time, which is a quantitative assessment that allows better comparison between results.
- 7 August 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (10) , 4613-4621
The dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
Aim: Tirzepatide (Tzp), a novel dual agonist glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1, is approved for treating insulin resistance and obesity, and menopausal women consuming a high‐calorie diet are a target to study the Tzp effect. Therefore, we aimed to allometrically scale body weight (BW) in Tzp‐treated obese diabetic menopausal mice. Materials and Methods: Three‐month‐old C57BL/6 female mice had bilateral ovariectomy (Ovx) or a sham procedure and for 12 weeks were fed a control diet or a high‐fat and high sucrose diet ( n = 120/each group [control (C), obese diabetic (Od), Ovx (O), sham (S), Tzp (T)]). Tzp was subcutaneously administered (10 nmol/kg) or vehicle once a day for an additional 4 weeks. The analysis considered log‐transformed data and the allometric equation log y = log a + b log x . Results: Od and OdO showed more upward slopes than C and CO. In C, BW was non‐allometric by T administration. Od and OdO showed slightly positive slopes (more prominent in OdO than Od). OdT and OdOT showed negative slopes, significant intercepts, and more robust Pearson coefficients than untreated ones. A potent drug effect was seen with BW allometric decline. Interactions between diet versus Ovx and diet versus Tzp affected weight gain. Diet versus Ovx versus Tzp affected food intake. Conclusions: A model was developed to show three usual factors observed in mature women. Notably, Tzp improved the metabolism and weight loss of OdO mice. Tzp‐treated mice showed negative allometric BW across treatment time, which is a quantitative assessment that allows better comparison between results.
- 24 June 2024
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 38 (6) , 1059-1068
Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
Background: Monotherapy to treat obesity‐associated liver insult is limited.Objectives: In diet‐induced obese mice showing metabolic dysfunction‐associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase‐4 inhibitor (DPP4i, linagliptin, L), and glucagon‐like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).Methods: Male 3‐month‐old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high‐fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D (n = 10/group).Results: HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed lower glucose intolerance (−60%), insulin (−61%), insulin resistance (−46%), TAG (−61%), and steatosis (−58%), and HF E + D showed lower glucose intolerance (−71%), insulin (−58%), insulin resistance (−62%), TAG (−61%), and steatosis (−82%). The principal component analysis (PCA) placed the HF group and the HF E + D group on opposite sides, while the HF E + L group was placed between C and HF E + D.Conclusion: PCA separated the groups considering the metabolism‐related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.
- 24 June 2024
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 38 (6) , 1059-1068
Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
Background: Monotherapy to treat obesity‐associated liver insult is limited.Objectives: In diet‐induced obese mice showing metabolic dysfunction‐associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase‐4 inhibitor (DPP4i, linagliptin, L), and glucagon‐like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).Methods: Male 3‐month‐old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high‐fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D (n = 10/group).Results: HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed lower glucose intolerance (−60%), insulin (−61%), insulin resistance (−46%), TAG (−61%), and steatosis (−58%), and HF E + D showed lower glucose intolerance (−71%), insulin (−58%), insulin resistance (−62%), TAG (−61%), and steatosis (−82%). The principal component analysis (PCA) placed the HF group and the HF E + D group on opposite sides, while the HF E + L group was placed between C and HF E + D.Conclusion: PCA separated the groups considering the metabolism‐related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.
- 16 April 2024
- Published by Elsevier in Life Sciences
- Vol. 346, 122645
Update on the transdifferentiation of pancreatic cells into functional beta cells for treating diabetes
- 16 April 2024
- Published by Elsevier in Life Sciences
- Vol. 346, 122645
Update on the transdifferentiation of pancreatic cells into functional beta cells for treating diabetes
- 12 July 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (11) , 1868-1876
AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression
Obesity is related to several organs, but the liver is particularly affected. Adenosine monophosphate‐activated protein kinase (AMPK) is a cellular energy sensor and regulator of liver lipid dysfunction and glucose metabolism. The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Together, these pathways are involved in obesity, insulin resistance, non‐alcoholic fatty liver disease (NAFLD) and its progression, and autophagy. During energy demand, liver kinase B (LKB) phosphorylation helps activate the AMPK/mTOR pathways. Likewise, the protein forkhead box O family (FOXO) negatively regulates adipogenesis by binding to the promoter sites of peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha, initiating adipogenesis. In addition, acetyl‐CoA carboxylase, which regulates de novo lipogenesis, is linked to LKB and FOXO in developing NAFLD. The kinase complex, consisting of Unc‐51‐like autophagy‐activating kinase 1 or 2 (ULK1, ULK2) by stimulating autophagy, and eliminating fat droplets in NAFLD, is regulated by mTORC1 and negatively regulated by AMPK that suppresses liver lipogenesis and increases fatty acid oxidation. Also, ULK1 is essential for initiating phagophore formation, establishing macrophagy, and generating autophagosomes. The selective breakdown of lipid droplets through macroautophagy, or macrolipophagy, occurs on a cellular energy level using free fatty acids. In addition, mTORC1 promotes lipogenesis by activating sterol regulatory element‐binding protein. Finding new components and novel regulatory modes in signaling is significant for a better understanding of the AMPK/mTOR pathways, potentially facilitating the development of future diagnostic and therapeutic strategies for NAFLD and its progression to non‐alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.
- 12 July 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (11) , 1868-1876
AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression
Obesity is related to several organs, but the liver is particularly affected. Adenosine monophosphate‐activated protein kinase (AMPK) is a cellular energy sensor and regulator of liver lipid dysfunction and glucose metabolism. The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Together, these pathways are involved in obesity, insulin resistance, non‐alcoholic fatty liver disease (NAFLD) and its progression, and autophagy. During energy demand, liver kinase B (LKB) phosphorylation helps activate the AMPK/mTOR pathways. Likewise, the protein forkhead box O family (FOXO) negatively regulates adipogenesis by binding to the promoter sites of peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha, initiating adipogenesis. In addition, acetyl‐CoA carboxylase, which regulates de novo lipogenesis, is linked to LKB and FOXO in developing NAFLD. The kinase complex, consisting of Unc‐51‐like autophagy‐activating kinase 1 or 2 (ULK1, ULK2) by stimulating autophagy, and eliminating fat droplets in NAFLD, is regulated by mTORC1 and negatively regulated by AMPK that suppresses liver lipogenesis and increases fatty acid oxidation. Also, ULK1 is essential for initiating phagophore formation, establishing macrophagy, and generating autophagosomes. The selective breakdown of lipid droplets through macroautophagy, or macrolipophagy, occurs on a cellular energy level using free fatty acids. In addition, mTORC1 promotes lipogenesis by activating sterol regulatory element‐binding protein. Finding new components and novel regulatory modes in signaling is significant for a better understanding of the AMPK/mTOR pathways, potentially facilitating the development of future diagnostic and therapeutic strategies for NAFLD and its progression to non‐alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.
- 12 April 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (6) , 101922
The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice
- 12 April 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (6) , 101922
The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice